GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (STU:AVU0) » Definitions » Cyclically Adjusted FCF per Share

Adverum Biotechnologies (STU:AVU0) Cyclically Adjusted FCF per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Cyclically Adjusted FCF per Share?

Note: As Cyclically Adjusted FCF per Share is a main component used to calculate Cyclically Adjusted Price-to-FCF. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Adverum Biotechnologies's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-2.116. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-09), Adverum Biotechnologies's current stock price is €13.40. Adverum Biotechnologies's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.00. Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF of today is .


Adverum Biotechnologies Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Adverum Biotechnologies's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Cyclically Adjusted FCF per Share Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -10.49 -11.01

Adverum Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.55 -10.59 -11.52 -11.01 -

Competitive Comparison of Adverum Biotechnologies's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF falls into.



Adverum Biotechnologies Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adverum Biotechnologies's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.116/131.7762*131.7762
=-2.116

Current CPI (Mar. 2024) = 131.7762.

Adverum Biotechnologies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 1.877 100.560 2.460
201409 -2.404 100.428 -3.154
201412 -1.932 99.070 -2.570
201503 -3.027 99.621 -4.004
201506 -3.599 100.684 -4.710
201509 -3.655 100.392 -4.798
201512 -3.317 99.792 -4.380
201603 -4.068 100.470 -5.336
201606 -2.344 101.688 -3.038
201609 -2.153 101.861 -2.785
201612 -2.099 101.863 -2.715
201703 -2.680 102.862 -3.433
201706 -2.460 103.349 -3.137
201709 -1.967 104.136 -2.489
201712 -2.254 104.011 -2.856
201803 -1.864 105.290 -2.333
201806 -1.581 106.317 -1.960
201809 -2.356 106.507 -2.915
201812 -1.800 105.998 -2.238
201903 -2.159 107.251 -2.653
201906 -1.956 108.070 -2.385
201909 -2.214 108.329 -2.693
201912 -3.208 108.420 -3.899
202003 -2.186 108.902 -2.645
202006 -2.216 108.767 -2.685
202009 -2.830 109.815 -3.396
202012 -1.992 109.897 -2.389
202103 -2.037 111.754 -2.402
202106 -3.181 114.631 -3.657
202109 -2.730 115.734 -3.108
202112 -2.717 117.630 -3.044
202203 -3.067 121.301 -3.332
202206 -3.374 125.017 -3.556
202209 -3.313 125.227 -3.486
202212 -1.763 125.222 -1.855
202303 -2.095 127.348 -2.168
202306 -2.133 128.729 -2.183
202309 -2.264 129.860 -2.297
202312 -1.950 129.419 -1.986
202403 -2.116 131.776 -2.116

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Adverum Biotechnologies  (STU:AVU0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Adverum Biotechnologies Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (STU:AVU0) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (STU:AVU0) Headlines

No Headlines